Skip to content
10-Q

Quarterly Report

Immunome, Inc. IMNM

0001558370-25-007382

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 87.01M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $30.8M
Current Liabilities Q1 2025 · Dec 31, 2024 $54.31M
Total Liabilities Q1 2025 · Mar 31, 2025 $35.57M
Total Liabilities Q1 2025 · Dec 31, 2024 $59.08M
Current Assets Q1 2025 · Mar 31, 2025 $323.13M
Current Assets Q1 2025 · Dec 31, 2024 $221.34M
Total Assets Q1 2025 · Mar 31, 2025 $342.69M
Total Assets Q1 2025 · Dec 31, 2024 $240.24M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $143.35M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $269.72M
Shares Diluted Q1 2025 · Mar 31, 2024 51.54M sh
Capex Q1 2025 · Mar 31, 2024 $2.16M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$11.17M
Stockholders Equity Q1 2025 · Mar 31, 2024 $285.57M
Stockholders Equity Q1 2025 · Dec 31, 2023 $119.88M
Eps Diluted Q1 2025 · Mar 31, 2024 −$2.51
Eps Basic Q1 2025 · Mar 31, 2024 −$2.51
Sga Expense Q1 2025 · Mar 31, 2024 $6.01M
Rd Expense Q1 2025 · Mar 31, 2024 $15.37M
Net Income Q1 2025 · Mar 31, 2024 −$129.49M
Operating Income Q1 2025 · Mar 31, 2024 −$132.3M
Revenue Q1 2025 · Mar 31, 2024 $1.03M